补脾肾化瘀毒法联合化疗治疗多发性骨髓瘤溶骨病变20例临床观察

Effect of Method of Bupishen-huayudu Combined with Chemotherapy in Treatment of Osteolytic Lesions in Multiple Myeloma

目的:探讨以补脾肾化瘀毒法治疗多发性骨髓瘤(MM)患者溶骨病变的临床疗效。方法:将40例MM患者随机分成2组,对照组20例予M2方案化疗,中药组20例予中药毒结清口服液60mL/d,同时予M2方案化疗。以血钙和CRP水平下降,骨痛的缓解和生活质量改善为评价指标。结果:中药组和对照组治疗后骨痛症状评分均明显下降,与治疗前比较差异均有显著性意义(P<0.05);中药组生活质量总有效率为70%与对照组总有效率(45%)比较差异均有显著性意义(P<0.05);中药组治疗后血钙和CRP水平均明显下降(P<0.05),与对照组治疗后血钙和CRP水平比较差异也有显著性意义(P<0.05);对照组治疗后血钙水平较治疗前下降(P>0.05);对照组CRP水平明显下降,与治疗前比较差异有显著性意义(P<0.05)。结论:补脾肾化瘀毒法联合化疗能有效降低MM患者血钙和CRP水平,改善骨痛症状,提高生活质量。

Objective ：To observe the effects of Bupishen-huayudu method in combination with Chemotherapy on patients with osleolytic lesions in Multiple Myeloma （ MM ）. Methods ：40Patients were randomly divided to two groups, control group were treated with M2 chemotherapy. In addition to M2 chemotherapy, TCM group were also treated with Dujieqing Liquor. Results ： Scores of bone ache in group TCM and in group control were lower than pretherapy（ P 〈 0. 05 ）. Total effective rate of life quality in group TCM was higher than those in group control （ P 〈 0. 05 ）. Blood calcium and CRP lever in group TCM were lower than those in group control（P 〈0. 05）. Conclusion：Method of bupishen-huayudu combined with Chemotherapy could degrade blood calcium and CRP lever,also could improve symptom of bone ache and quality of life.